These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
232 related articles for article (PubMed ID: 24585370)
21. Protection of rhesus macaques from vaginal infection by vaginally delivered maraviroc, an inhibitor of HIV-1 entry via the CCR5 co-receptor. Veazey RS; Ketas TJ; Dufour J; Moroney-Rasmussen T; Green LC; Klasse PJ; Moore JP J Infect Dis; 2010 Sep; 202(5):739-44. PubMed ID: 20629537 [TBL] [Abstract][Full Text] [Related]
22. Combination Pod-Intravaginal Ring Delivers Antiretroviral Agents for HIV Prophylaxis: Pharmacokinetic Evaluation in an Ovine Model. Moss JA; Butkyavichene I; Churchman SA; Gunawardana M; Fanter R; Miller CS; Yang F; Easley JT; Marzinke MA; Hendrix CW; Smith TJ; Baum MM Antimicrob Agents Chemother; 2016 Jun; 60(6):3759-66. PubMed ID: 27067321 [TBL] [Abstract][Full Text] [Related]
23. Preparation of multiparticulate vaginal tablet using glyceryl monooleate for sustained progesterone delivery. Biradar SV; Dhumal RS; Shah MH; Paradkar AR; Yamamura S Pharm Dev Technol; 2009; 14(1):38-49. PubMed ID: 18802845 [TBL] [Abstract][Full Text] [Related]
24. Zinc acetate/carrageenan gels exhibit potent activity in vivo against high-dose herpes simplex virus 2 vaginal and rectal challenge. Fernández-Romero JA; Abraham CJ; Rodriguez A; Kizima L; Jean-Pierre N; Menon R; Begay O; Seidor S; Ford BE; Gil PI; Peters J; Katz D; Robbiani M; Zydowsky TM Antimicrob Agents Chemother; 2012 Jan; 56(1):358-68. PubMed ID: 22064530 [TBL] [Abstract][Full Text] [Related]
25. Advances in development, scale-up and manufacturing of microbicide gels, films, and tablets. Garg S; Goldman D; Krumme M; Rohan LC; Smoot S; Friend DR Antiviral Res; 2010 Dec; 88 Suppl 1():S19-29. PubMed ID: 21109064 [TBL] [Abstract][Full Text] [Related]
26. Biocompatibility of solid-dosage forms of anti-human immunodeficiency virus type 1 microbicides with the human cervicovaginal mucosa modeled ex vivo. Trifonova RT; Pasicznyk JM; Fichorova RN Antimicrob Agents Chemother; 2006 Dec; 50(12):4005-10. PubMed ID: 17030562 [TBL] [Abstract][Full Text] [Related]
27. Vaginal microbicides and the prevention of HIV transmission. Cutler B; Justman J Lancet Infect Dis; 2008 Nov; 8(11):685-97. PubMed ID: 18992405 [TBL] [Abstract][Full Text] [Related]
28. Squeezing flows of vaginal gel formulations relevant to microbicide drug delivery. Kieweg SL; Katz DF J Biomech Eng; 2006 Aug; 128(4):540-53. PubMed ID: 16813445 [TBL] [Abstract][Full Text] [Related]
29. Vaginal microbicide gel for delivery of IQP-0528, a pyrimidinedione analog with a dual mechanism of action against HIV-1. Mahalingam A; Simmons AP; Ugaonkar SR; Watson KM; Dezzutti CS; Rohan LC; Buckheit RW; Kiser PF Antimicrob Agents Chemother; 2011 Apr; 55(4):1650-60. PubMed ID: 21245437 [TBL] [Abstract][Full Text] [Related]
30. Development and characterization of a solid dispersion film for the vaginal application of the anti-HIV microbicide UAMC01398. Grammen C; Van den Mooter G; Appeltans B; Michiels J; Crucitti T; Ariën KK; Augustyns K; Augustijns P; Brouwers J Int J Pharm; 2014 Nov; 475(1-2):238-44. PubMed ID: 25175729 [TBL] [Abstract][Full Text] [Related]
31. Biophysical characterization of small molecule antiviral-loaded nanolipogels for HIV-1 chemoprophylaxis and topical mucosal application. Ramanathan R; Jiang Y; Read B; Golan-Paz S; Woodrow KA Acta Biomater; 2016 May; 36():122-31. PubMed ID: 26947382 [TBL] [Abstract][Full Text] [Related]
32. Recent advances on anti-HIV vaginal delivery systems development. Antimisiaris SG; Mourtas S Adv Drug Deliv Rev; 2015 Sep; 92():123-45. PubMed ID: 25858666 [TBL] [Abstract][Full Text] [Related]
33. Specific microbicides in the prevention of HIV infection. Kelly CG; Shattock RJ J Intern Med; 2011 Dec; 270(6):509-19. PubMed ID: 21917029 [TBL] [Abstract][Full Text] [Related]
34. Preclinical studies on thiocarboxanilide UC-781 as a virucidal agent. Balzarini J; Naesens L; Verbeken E; Laga M; Van Damme L; Parniak M; Van Mellaert L; Anné J; De Clercq E AIDS; 1998 Jul; 12(10):1129-38. PubMed ID: 9677161 [TBL] [Abstract][Full Text] [Related]
35. Inhibition of vaginal transmission of HIV-1 in hu-SCID mice by the non-nucleoside reverse transcriptase inhibitor TMC120 in a gel formulation. Di Fabio S; Van Roey J; Giannini G; van den Mooter G; Spada M; Binelli A; Pirillo MF; Germinario E; Belardelli F; de Bethune MP; Vella S AIDS; 2003 Jul; 17(11):1597-604. PubMed ID: 12853741 [TBL] [Abstract][Full Text] [Related]
36. Partial protection against multiple RT-SHIV162P3 vaginal challenge of rhesus macaques by a silicone elastomer vaginal ring releasing the NNRTI MC1220. Fetherston SM; Geer L; Veazey RS; Goldman L; Murphy DJ; Ketas TJ; Klasse PJ; Blois S; La Colla P; Moore JP; Malcolm RK J Antimicrob Chemother; 2013 Feb; 68(2):394-403. PubMed ID: 23109186 [TBL] [Abstract][Full Text] [Related]
37. SHIV-162P3 infection of rhesus macaques given maraviroc gel vaginally does not involve resistant viruses. Tsibris AM; Pal U; Schure AL; Veazey RS; Kunstman KJ; Henrich TJ; Klasse PJ; Wolinsky SM; Kuritzkes DR; Moore JP PLoS One; 2011; 6(12):e28047. PubMed ID: 22164225 [TBL] [Abstract][Full Text] [Related]
38. Vaginal microbicides: moving ahead after an unexpected setback. van de Wijgert JH; Shattock RJ AIDS; 2007 Nov; 21(18):2369-76. PubMed ID: 18025873 [No Abstract] [Full Text] [Related]
39. Formulation studies of benzydamine mucoadhesive formulations for vaginal administration. Perioli L; Ambrogi V; Venezia L; Giovagnoli S; Pagano C; Rossi C Drug Dev Ind Pharm; 2009 Jul; 35(7):769-79. PubMed ID: 19337872 [TBL] [Abstract][Full Text] [Related]